Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating on Arrowhead Pharma and increased its price target from $110 to $126. This indicates a positive outlook from the analyst, suggesting potential upside for the stock based on their valuation.
Piper Sandler analyst Edward Tenthoff reiterated an 'Overweight' rating on Arrowhead Pharma (ARWR) and raised the price target from $110 to $126. This action signals continued confidence from a prominent analyst in the company's future performance and valuation. For traders, this could lead to short-term positive sentiment and potentially increased buying activity as the higher price target suggests significant upside. The long-term implication is a reinforced positive outlook for ARWR, potentially attracting more institutional interest. A key opportunity for traders is to capitalize on any immediate upward movement driven by this analyst upgrade.